Information for medical professionals

 

Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine


ISTH Statement on COVID-19 and Venous Thromboembolism (VTE)
 

A Systematic Approach for Managing Venous Thromboembolism in Patients with COVID-19: A Multinational Consensus Statement from the International Society on Thrombosis and Haemostasis (ISTH) on Behalf of the International Thrombosis Community

Our Society contributed to this statement together with 70 other organizations around the world

This information can also be found on the ISTH Website: https://www.isth.org/news/517212


AHA/ISTH SCIENTIFIC STATEMENT

Venous Thromboembolism Research Priorities

Venous thromboembolism is a major cause of morbidity and mortality. The impact of the US Surgeon General’s The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has been lower than expected given the public health impact of this disease. This scientific statement highlights future research priorities in venous thromboembolism, developed by experts and a crowdsourcing survey across 16 scientific organizations.


Recommendations for the management of coagulopathies associated with COVID-19

 

AVAILABLE NOW:  documents on anticoagulation in COVID-19 prepared by a group of national experts

 
The experts:
  • Executive board members BSTH: Prof Cécile Oury (ULiège, President), Dr Thomas Vanassche (UZ Leuven, Vice-President), Dr Kristel Vandenbosch (CHU Liège, Treasurer), Christelle Orlando (UZ Brussel, Secretary) 
  • UAntwerpen: Prof Alain Gadisseur (UZ Antwerepen) (BSTH member, former President)
  • VUB: Prof Kristin Jochmans (UZ Brussel) (BSTH member, former President)
  • UCL: Prof Cedric Hermans (Woluwe Clinique St Luc) (BSTH members)
  • ULB: Prof Serge Motte (Hôpital Erasme) (BSTH member, former President)
  •  ULiège: Dr Muriel Sprynger (CHU Liège), President of the Belgian Working Group of Angiology (BSTH member); Dr Pierre Péters (CHU Liège) (BSTH member)
  • KULeuven: Prof Peter Verhamme (UZ Leuven) (BSTH member); Prof Christophe Vandenbriele (UZ Leuven) (BSTH member)
  • UGent: Prof Harlinde Peperstraete (UZ Gent) (BSTH member)
  • Dr Jean-Marc Minon (CHR Citadelle – Hôpital public de Liège) (BSTH member)
  • Dr Roel Van Giels (Domus Medica)
  • Dr Patrick Emonts (Groupement des gynécologues obstétriciens de langue française de Belgique, GGOLFB, CHU Liège)
  • Dr Isabelle Dehaene (Vlaamse Vereniging voor Obstetrie en Gynaecologie, VVOG, UZ Gent)
 

ISTH recommandations and practical guidance

ISTH recommendations and practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19

 

 


BSTH database of special haemostasis assays

Links to: BSTH database of special haemostasis assays in Belgium

 


BSTH working groups

  • Thrombosis Guidelines Group (TGG)
  • Bleeding Disorders Group (BDG)
  • BSTH working group on fibrinogen

Interested collaborators are continuously looked for.
Please contact prof. Peter Verhamme (TGG) or prof. Alain Gadisseur (BDG)


 

Brochures & booklets

Anticoagulation booklets


Order booklets

Boehringer Ingelheim
Nicole Devreese

tel: +32 2 7733392
fax: +32 2 7733367

email

Daiichi-Sankyo
Nathalie Demeester

tel: +32 10 489595
fax: +32 10 489589

email

GSK
Caroline Legrand

tel: +32 10 853035
fax: +32 2 4010668

email

Leo Pharma
Kathleen Bierinckx

tel: +32 3 7407864
fax: +32 3 7407869

email

Sanofi
Fabienne Drappier

tel: +32 2 7105465
fax: +32 2 7105729

email


"New oral anticoagulants (NOACs)" brochures



Order brochure

Boehringer Ingelheim
Nicole Devreese

tel: +32 2 7733392
fax: +32 2 7733367

email

CSL Behring

tel: +32 15 288920
fax: +32 15 207435

email

© Copyright 2024 - Belgian Society on Thrombosis and Haemostasis - All rights reserved.